Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04605094 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
NCT04605094 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 194 participants.
The verdict
NCT04605094, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the efficacy and safety of benralizumab versus placebo and to compare benralizumab dosing regimens during extension period.
Interventions
- BIOLOGICAL Benralizumab
- BIOLOGICAL Placebo / Benralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2022-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04605094
The ClinicalTrials.gov registry entry for NCT04605094 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Benralizumab is the first listed.
NCT04605094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04605094 about?
NCT04605094 is a clinical study titled "Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis". The purpose of the study is to compare the efficacy and safety of benralizumab versus placebo and to compare benralizumab dosing regimens during extension period.
What is the current status of trial NCT04605094?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2020-11-12. Estimated completion is 2022-09-13.
What interventions are being tested in trial NCT04605094?
The interventions under investigation include: Benralizumab (BIOLOGICAL), Placebo / Benralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04605094?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.